South Korean biopharmaceutical company GC Biopharma (KRX: 006280) announced on Wednesday that its US subsidiary, ABO Holdings, has received US Food and Drug Administration (FDA) approval for its plasma collection centre in Calexico, California.
The approval follows GC Biopharma's recent acquisition of ABO Holdings in January 2025, a strategic move aimed at supporting the long-term revenue potential of ALYGLO, its immune globulin intravenous product, which was recently launched in the US market.
With this authorisation, ABO Holdings now operates six plasma collection centres across California, Utah, and New Jersey. The company plans to intensify donor recruitment efforts in the second quarter to support expanded operations.
ABO Holdings is also constructing two additional plasma centres in Texas, with FDA approval targeted by 2027.
GC Biopharma anticipates that its source plasma business will enter into a phase of gradual growth in the latter half of 2025.
Galderma's nemolizumab recommended for NHS funding in England and Wales for atopic dermatitis
Merck launches Phase 3 trial for dengue vaccine candidate V181
FDA grants priority review to Innoviva's zoliflodacin for treatment of gonorrhea
AB Science secures Canadian patent for AB8939, completing global IP coverage for AML treatment
Mezzion Pharma obtains USD20m funding for udenafil Phase 3 clinical development for Fontan patients
UCB announces BIMZELX (bimekizumab-bkzx) three-year data at EULAR 2025
US FDA approves expanded indication for AbbVie's MAVYRET (glecaprevir/pibrentasvir) in acute HCV
MaxCyte and Ori Biotech partner to advance autologous cell therapy manufacturing
OptiBiotix announces publication of positive SlimBiome study in European Journal of Nutrition
Crossject advances paediatric development of ZEPIZURE Junior for epilepsy crisis management
Bayer and Broad Institute extend cardiovascular research alliance to advance precision therapies